NCT06265038 Confirmatory Investigation to Evaluate the Performance and Safety of ReSpace TiCell Cage Implants in TLIF
| NCT ID | NCT06265038 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sanatmetal Orthopaedic and Traumatologic Equipment Manufacturer Ltd. |
| Condition | Degenerative Instability |
| Study Type | INTERVENTIONAL |
| Enrollment | 99 participants |
| Start Date | 2024-02-01 |
| Primary Completion | 2026-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 99 participants in total. It began in 2024-02-01 with a primary completion date of 2026-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary objective of this study is to confirm superiority for the efficacy of the ReSpace Ticell Cage implants in Transforaminal Lumbar Interbody Fusion compared to state-of-the-art. The secondary objective of the study is to evaluate further efficacy and safety of the ReSpace Ticell Cage implants in Transforaminal Lumbar Interbody Fusion with the following secondary efficacy and safety objectives: * To evaluate if implantation causes significant reduction in patient's back, hip/buttock, and leg pain. * To evaluate if implantation causes significant increase quality of life of the patients. * To evaluate if using the device can be considered as safe overall.
Eligibility Criteria
Inclusion Criteria: Each subject must meet all the following criteria to be enrolled in this study: All subjects who had previously indicated for TLIF surgery can participate in this study, with the following evidence: 1. Has degenerative disease of the lumbosacral spine in one or two adjacent levels (L1 to S1), manifested by: 1. Low back pain, or 2. Irradiating leg or buttock pain, paresthesia, numbness, or weakness, or 3. History of neurogenic claudication. 2. Has radiographic evidence (e.g. CT, MRI, x-ray, etc.) of degenerative lumbosacral disease including at least one of the following: 1. Instability as defined by ≥3 mm translation or ≥5-degree angulation 2. Decreased disc height, on average by ≥2 mm, but dependent upon the spinal level 3. Scarring/thickening of ligamentum flavum or annulus fibrosis 4. Herniated nucleus pulposus 5. Vacuum phenomenon 6. Grade 1 spondylolisthesis/retrolisthesis based on the Meyerding classification (Meyerding, Henry William, 1932), or lateral listhesis demonstrated by coronal plane translation (slippage) of the superior (cranial) vertebral body lateral to the inferior (caudal) vertebral body less than or equal to 3mm, or 7. Stenosis, or narrowing, of the lumbar spinal canal and/or intervertebral foramen requiring significant decompression leading to segmental instability, or 8. Recurrent disc herniation Further inclusion criteria: * Skeletally mature adults ages 18 - 80 years of age * Able to read and understand all documents used in this study, including the informed consent and patient-reported outcome questionnaires Exclusion Criteria: Subjects meeting any of the following criteria will be excluded from the study: 1. Prior surgical procedure at the involved or adjacent spinal levels (e.g. stabilization, fusion, arthroplasty and/or other non-fusion procedures). Prior microdiscectomy, discectomy, laminectomy, decompression surgery at the target or adjacent levels is allowed. 2. Significant lumbar instability defined as sagittal listhesis greater than Grade 2 at any involved level using the Meyerding Classification or lateral listhesis greater than 3 mm at any involved level. 3. Planned use of an internal or external bone growth stimulator. 4. Lumbar scoliosis \>30 degrees. 5. Patients who had a previous diagnosis of osteoporosis with a Tscore of -2.5 or below in the last 12 months. If subject has a prevalent fragility fracture and a T-score hasn't been assessed in the last 12 months, a DEXA (dual x-ray absorptiometry) scan will need to be obtained. 6. Morbidly obese, as defined by a Body Mass Index (BMI) \>40. 7. Presence of active malignancy or prior history of malignancy (noninvasive basal cell carcinoma of the skin and non-invasive squamous cell carcinoma localized only to the skin is allowed). 8. Overt or active bacterial infection, either local to surgical space or systemic. 9. Has undergone administration of any type of corticosteroid, antineoplastic, immunostimulant, or immunosuppressive agents, or medications known to inhibit with the healing of bone or soft tissue within 30 days prior to implantation of the assigned treatment 1. This includes patients ≥ 65 years of age taking warfarin with documented diagnosed osteoporosis. All other patients taking warfarin should washout for at least 5 days prior to treatment 2. Use of steroidal inhalers, short-term NSAID use, and shortterm steroidal use (e.g. Medrol Dosepak) is allowed pre and postoperatively. For this clinical study, short-term use is defined as ≤ two weeks. 3. Use of NSAIDs and/or steroids for longer than two weeks postoperatively through the 24 Month Follow-Up Visit is not recommended. Such patients must be excluded from data analysis in case of non-fusion. 10. Co-morbidities, which in the investigator's opinion, precludes the subject from being a surgical candidate. 11. Autoimmune disease, which in the investigator's opinion, is known to affect bone metabolism or the spine (e.g., spondyloarthropathies, juvenile arthritis, rheumatoid arthritis, Graves' disease, Hashimoto's thyroiditis). 12. Any endocrine or metabolic disorder, which in the investigator's opinion, is known to affect osteogenesis (e.g., Paget's disease, renal osteodystrophy, Ehlers-Danlos syndrome, or osteogenesis imperfecta). 13. Known hypersensitivity or allergy to any components of the study treatments including, but not limited to bone morphogenetic proteins (BMPs); injectable collagen; protein pharmaceuticals (e.g.: monoclonal antibodies or gamma globulins); bovine collagen products; and/or instrumentation materials (e.g., titanium, titanium alloy, cobalt chrome, cobalt chrome alloy, or PEEK). 14. History of any allergy resulting in anaphylaxis. 15. Is mentally incompetent. If questionable, obtain psychiatric consult. 16. Treatment with an investigational therapy (drug, device, and/or biologic) targeting spinal conditions within 3 months prior to implantation surgery, treatment with any other investigational therapies within 30 days prior to implantation surgery, or such treatment is planned during the 24-month period following implantation of the study treatment. 17. Pregnancy and breastfeeding. 18. A documented diagnosis of substance use disorder (Nicotine use is allowed.) 19. Any condition, which in the investigator's opinion, would interfere with the subject's ability to comply with study instructions, which might confound data interpretation. 20. Subject is considered to belong to a vulnerable population.
Contact & Investigator
Aron Lazary, MD, PhD
PRINCIPAL INVESTIGATOR
National Center for Spinal Disorders
Frequently Asked Questions
Who can join the NCT06265038 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Degenerative Instability. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06265038 currently recruiting?
Yes, NCT06265038 is actively recruiting participants. Contact the research team at bkozma@sanatmetal.hu for enrollment information.
Where is the NCT06265038 trial being conducted?
This trial is being conducted at Budapest, Hungary.
Who is sponsoring the NCT06265038 clinical trial?
NCT06265038 is sponsored by Sanatmetal Orthopaedic and Traumatologic Equipment Manufacturer Ltd.. The principal investigator is Aron Lazary, MD, PhD at National Center for Spinal Disorders. The trial plans to enroll 99 participants.